Fresh from rebrand, Spyre Therapeutics raises $180M as it steers TLA1 program to clinic
Spyre Therapeutics is pulling in $180 million in a private placement just a couple of weeks after it rebranded from Aeglea BioTherapeutics.
Spyre is selling 6 million shares of its common stock at $15 per share and 150,000 shares of its Series B preferred stock at $600 per share in a private placement. It’s expected to close around Dec. 11.
The private placement will extend the biotech’s cash runway into the second half of 2026 and support development of its pipeline for general corporate purposes and working capital.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.